Harbour BioMed has established a robust pipeline in oncology and immunology since the company was established in 2016. The current portfolio includes five clinical-stage in-licensed compounds and a rapidly emerging set of therapeutics coming from its internal discovery efforts as well as co-discovery/development collaborations with academic institutions and biopharmaceutical companies.
HBM's Immunology Products Pipeline

HBM's Immuno-oncology Products Pipeline